LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hurt, C. S.; Alkufri, F.; Brown, R. G.; Burn, D. J.; Hindle, J. V.; Landau, S.; Wilson, K. C.; Samuel, M.; PROMS-PD study group, (2014)
Languages: English
Types: Article
Subjects: RC
BACKGROUND: Dopaminergic drugs are the primary risk factor for Impulse Control Behaviours (ICB) in Parkinson's disease (PD), others being early-onset disease and gender.\ud \ud OBJECTIVE: This report further explores ICB symptom relationships with motor and mood phenotypes, the complex relationship with dopaminergic medications, and hypothesizes a model with potential clinical implications.\ud \ud METHODS: Data from 500 PD patients were analyzed. Hypersexuality, gambling and shopping behaviour were assessed using selected questions from the Minnesota Impulsive Disorders Interview questionnaire. Local questions assessed hobbyism. Motor characteristics considered were akinetic-rigid/gait disturbance (PIGD) and 'non-PIGD' phenotypes, motor severity, motor progression, and presence/absence of motor fluctuations. Other variables included anxiety, depression, current levodopa and agonist use, age, gender and cognition.\ud \ud RESULTS: Overall, ICB symptom frequency was 17.8%. There was no relationship between PIGD/non-PIGD motor phenotypes and ICB symptoms. Those with ICB symptoms had higher total combined levodopa/agonist equivalent intake, but not current agonist-only equivalent intake. ICB symptoms were reported by 23.1% of those taking combined levodopa and agonist compared to 19.2% on agonist monotherapy and 11.6% levodopa monotherapy. Compared with non-ICB patients, patients with ICB symptoms were more likely to show an anxious mood phenotype, reported more motor fluctuations, and were younger.\ud \ud CONCLUSIONS: Both PIGD and non-PIGD phenotypes are equally affected. Dose-related risk applies to total anti-parkinsonian medication and not just current agonist-only. Anxious mood phenotypes may carry increased risk. A role of anxiety, either as a marker of risk, indirect causal factor, or maintaining factor is incorporated into a preliminary model. We discuss implications for clinical management.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [13] Burn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS, Brown RG; PROMS-PD Study Group (2012) Parkinson's disease motor subtypes and mood. Movement Disord 27(3), 379-86.
    • [14] Rodriguez-Blazquez C, Frades-Payo B, Forjaz MJ, de Pedro-Cuesta J, MartinezMartin P (2009) Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease. Movement Disord 24(4),519-25.
    • [15] Reyes MA, Perez-Lloret S, Roldan Gerschcovich E, Martin ME, Leiguarda R, Merello M (2009) Addenbrooke's Cognitive Examination validation in Parkinson's disease. Euro J Neurol 16(1), 142-7.
    • [16] Christenson GA, Faber RJ, de Zwaan M, Raymond NC, Specker SM, Ekern MD, Mackenzie TB, Crosby RD, Crow SJ, Eckert ED, et al. (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiat 55(1), 5-11.
    • [17] Singh-Curry V, Bunzeck N, O'Sullivan S, Molloy M, Perry R, Bain P, et al (2010) PATH50 Novelty-seeking and risk-taking behaviour in subtypes of Parkinson's disease. J Neurol Neurosur Ps. 81(11), e21.
    • [18] Wylie SA, van den Wildenberg W, Ridderinkhof KR, Claassen DO, Wooten GF, Manning CA (2012) Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. J Neurol Neurosur Ps 83(12), 1149-54.
    • [19] Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, Stacy M (2011) Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol 69(6), 986-96.
    • [20] Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurology 5(4), 355-63.
    • [21] Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, [23] Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ (2013). Prospective cohort study of impulse control disorders in Parkinson's disease. Movement Disord 28(3), 327-33.
    • [24] Santangelo G, Barone P, Trojano L, Vitale C (2013) Pathological gambling in Parkinson's disease. A comprehensive review. Parkinsonism Relat Disord 19(7), 645-53.
    • [25] Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6), 963-8.
    • [26] Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M (2012) Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease? Movement Disord 27(2), 236-41.
    • [27] Poletti M, Bonuccelli U (2012) Personality traits in patients with Parkinson's disease: assessment and clinical implications. J Neurol 259(6), 1029-38.
    • [28] Jacobs H, Heberlein I, Vieregge A, Vieregge P (2001) Personality traits in young patients with Parkinson's disease. Acta Neurol 103(2), 82-7.
    • [29] Okai D, Samuel M, Askey-Jones S, David AS, Brown RG (2011) Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework. Euro J Neurol 18(12), 1379-83.
    • [30] Delaney M, Simpson J, Leroi I (2012) Perceptions of cause and control of impulse control behaviours in people with Parkinson's disease. Brit J Health Psyc 17(3), 522-35.
    • [31] Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR, Martin A, Mack J, Brown RG, David AS (2013) Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80(9), 792-9.
    • [32] Potenza MN, Voon V, Weintraub D (2007) Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neuro 3(12), 664-72.
    • [33] Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, Lang AE, Miyasaki J (2006) Prospective prevalence of pathologic gambling and medication association in Parkinson's disease. Neurology 66(11), 1750-2.
    • [34] Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson's disease. Arch Neurol 67(1), 58-63.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article